| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Addressing the dual challenge: Managing smoking cessation in patients with diabetes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Cristina Russo, Magdalena Walicka, Gal Cohen, Carlo Maria Bellanca, Giulio Geraci, Pasquale Caponnetto, Dario Elvio Noviello, Roberta Chianetta, Jacob George, Roberta Sammut, Eward Franek and Riccardo Polosa |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the NextGenerationEU of the European Union |
PNRR 341/2022 |
|
| Corresponding Author |
Riccardo Polosa, MD, PhD, Faculty of Medicine and Surgery, Kore University of Enna, Viale delle Olimpiadi 1, Enna 94100, Sicilia, Italy. polosa@unict.it |
| Key Words |
Diabetes; Smoking cessation; Harm reduction; Glucagon-like peptide 1 analogues; Digital health technologies; Wearable sensors |
| Core Tip |
This expert review addresses the dual challenge of smoking cessation in patients with type 2 diabetes - a high‐risk group experiencing synergistic vascular damage from chronic hyperglycemia and tobacco smoke toxicants. It underscores the evidence for (and limitations of) standard smoking cessation medications (i.e., nicotine replacement therapy, bupropion, and varenicline) while introducing emerging harm reduction strategies (i.e., e-cigarettes and heated tobacco products) and cutting-edge innovations (i.e., glucagon-like peptide-1 analogues and digital health tools). Adopting a holistic, patient-centered approach is crucial for improving the lives of people with diabetes who smoke, but further research to enhance long‐term cessation success and improve metabolic outcomes will be necessary. |
| Publish Date |
2025-12-15 09:46 |
| Citation |
Russo C, Walicka M, Cohen G, Bellanca CM, Geraci G, Caponnetto P, Noviello DE, Chianetta R, George J, Sammut R, Franek E, Polosa R. Addressing the dual challenge: Managing smoking cessation in patients with diabetes. World J Diabetes 2025; 16(12): 105241 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i12/105241.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i12.105241 |
